Side-by-side · Research reference
CrystagenvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED12/40 cited
BFDA-ApprovedFlagship15/53 cited
Crystagen
Khavinson Bioregulator · Immune-Thymic
SQ · Protocol variable
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Crystagen
Semaglutide
Primary target
B-lymphocytes in splenic tissueСhervyakova 2014
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
B-cell activation → Immune modulation during agingСhervyakova 2014
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Unknown — bioregulator mechanism not fully characterized
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Crystagen
Semaglutide
Standard dose
Not standardized — variable protocols
Russian bioregulator literature does not specify unified human dosing.
—
Evidence basis
Animal / mechanistic
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Route
Subcutaneous (presumed from bioregulator class)
—
Frequency
Unknown — bioregulator protocols variable
Once weekly, same day each week
Duration
Unknown — chronic administration presumed in animal models
Indefinite for chronic indication
Discontinuation results in weight regain.
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
Crystagen
Semaglutide
Published adverse events
None reported in available animal literature
—
Human safety data
Absent — no controlled human trials identified
—
Autoimmune considerations
Theoretical concern with B-cell modulators in predisposed individuals
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Crystagen
- ·Active autoimmune disease (theoretical)
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Crystagen
- ·Pregnancy / lactation (no data)
- ·Active B-cell malignancies
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Crystagen
Semaglutide
1. Route
Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Reconstitution
Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
—
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Crystagen
+ Vilon
Multi-pathwayVilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.
- Crystagen
- Dose unknown · SQ
- Vilon
- Dose unknown · SQ
- Frequency
- Protocol variable
- Primary benefit
- Broader thymic-immune coverage (T-cell + B-cell)
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)